The involvement of the μ-opioid receptor in gastrointestinal pathophysiology: Therapeutic opportunities for antagonism at this receptor

Pharmacology and Therapeutics

Volumn 117, Issue 1, 2008, Pages 162-187

  DeHaven Hudkins, Diane L ^a   DeHaven, Robert N ^a   Little, Patrick J ^a   Techner, Lee M ^a  

^a ADOLOR CORPORATION   (United States)

Author keywords

Alvimopan; Constipation; Gastrointestinal; Ileus; Methylnaltrexone; Opioid induced bowel dysfunction

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; MU OPIATE RECEPTOR; OPIATE ANTAGONIST;

ANALGESIA; CONSTIPATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL DISEASE; IN VITRO STUDY; IN VIVO STUDY; INTESTINAL DYSMOTILITY; IRRITABLE COLON; NONHUMAN; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; REVIEW;

ANALGESICS, OPIOID; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID, MU;

EID: 36549022611     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2007.09.007     Document Type: Review

References (128)

1. Allan L., Hays H., Jensen N.-H., de Waroux B.L., Bolt M., Donald R., et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322 (2001) 1-7
2. Amin H.M., Sopchak A.M., Foss J.F., Esposito B.F., Roizen M.F., and Camporesi E.M. Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. Anesth Analg 78 (1994) 701-705
3. Anonymous. (2005). GlaxoSmithKline and Adolor report initial results from Phase 2 studies of Entereg™ (alvimopan). GlaxoSmithKline press release, March 8, 2005.
4. Aung H.H., Mehendale S.R., Xie J.-T., Moss J., and Yuan C.-S. Methylnaltrexone prevents morphine-induced kaolin intake in the rat. Life Sci 74 (2004) 2685-2691
5. Awouters F., Niemegeers C.J.E., and Janssen P.A.J. Pharmacology of antidiarrheal drugs. Annu Rev Pharmacol Toxicol 23 (1983) 279-301
6. Awouters F., Megens A., Verlinden M., Schuurkes J., Niemegeers C., and Janssen P.A. Loperamide. Survey of studies on mechanism of its antidiarrhea activity. Dig Dis Sci 38 (1993) 977-995
7. Argentieri T.M., and McArdle J.J. Interaction of the opiate antagonist, naltrexone methyl bromide, with the acetylcholine receptor system of the motor end-plate. Brain Res 277 (1983) 377-379
8. Bagnol D., Mansour A., Akil H., and Watson S.J. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience 81 (1997) 579-591
9. Barr W.H., Nguyen P., Slattery M., Russell R., and Carpenter R.L. ADL 8-2698 reverses opioid induced delay in colonic transit. Clin Pharm Ther 67 (2000) 91
10. Behm B., and Stollman N. Postoperative ileus: etiologies and interventions. Clin Gastroenterol Hepatol 1 (2003) 71-80
11. Bianchi G., Fiocchi R., Tavani A., and Manara L. Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity. Life Sci 30 (1982) 1875-1883
12. Brown D.R. The use and misuse of quaternary ammonium opiate antagonists. Trends Pharmacol Sci 6 (1985) 394-395
13. Brown D.R., and Goldberg L.I. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24 (1985) 181-191
14. Brown D.R., Robertson M.J., and Goldberg L.I. Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quaternary derivatives. Neuropharmacology 22 (1983) 317-321
15. Callaghan J.T., Cerimele B., Nowak T.V., DeLong A., Myhart E., and Oldham S. Effect of the opioid antagonist LY 246736 on gastrointestinal transit in human subjects. Gastroenterology 114 (1998) G3015
16. 3H]alvimopan binding to the cloned human μ-opioid receptor. Eur J Pharmacol 520 (2005) 29-36
17. Culpepper-Morgan J.A., Inturrisi C.E., Portenoy R.K., Foley K., Houde R.W., Marsh F., et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 52 (1992) 90-95
18. Dashwood M.R., Debnam E.S., Bagnall J., and Thomson C.S. Autoradiographic localisation of opioid receptors in rat small intestine. Eur J Pharmacol 107 (1985) 267-269
19. 3H]loperamide binding to opioid receptors in rat and human small intestine. Prog Clin Biol Res 328 (1990) 165-169
20. 35S]GTPγS binding by ADL 8-2698, a potent opioid receptor antagonist. Soc Neurosci Abstr 26 (2000) 283.13
21. DeHaven-Hudkins D.L. Peripherally restricted opioid drugs - advances and retreats. Curr Opin Anaesthesiol 16 (2003) 541-545
22. DeHaven-Hudkins D.L., and Dolle R.E. Peripherally restricted opioid agonists as novel analgesic agents. Curr Pharm Des 10 (2004) 743-757
23. Delaney C.P. Clinical perspective on postoperative ileus and the effect of opiates. Neurogastroenterol Motil 16 Suppl 2 (2004) 61-66
24. Delaney C.P., Weese J.L., Hyman N.H., Bauer J., Techner L., Gabriel K., et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 48 (2005) 1114-1129
25. De Luca A., and Coupar I.M. Insights into opioid action in the intestinal tract. Pharmacol Ther 69 (1996) 103-115
26. + conductance. Scand J Gastroenterol 36 (2001) 731-737
27. Fallon M.T. Constipation in cancer patients: prevalence, pathogenesis, and cost-related issues. Eur J Pain 3 Suppl A (1999) 3-7
28. Fickel J., Bagnol D., Watson S.J., and Akil H. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Mol Brain Res 46 (1997) 1-8
29. Follefant R.L., Hardy G.W., Lowe L.A., Schneider C., and Smith T.W. Antinociceptive effects of the novel opioid peptide BW443C compared with classical opiates; peripheral versus central actions. Br J Pharmacol 93 (1988) 85-92
30. Foss J.F. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 182 (2001) 19S-26S
31. Foss J.F., Bass A.S., and Goldberg L.I. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharmacol 33 (1993) 747-751
32. Foss J.F., Yuan C.S., Attele A., Toledano A., Sellers D., Roizen M.F., et al. Methylnaltrexone does not antagonize the analgesic effect of morphine: a clinical study. Anesthesiology 83 (1995) A361
33. Foss J.F., O'Connor M.F., Yuan C.-S., Murphy M., Moss J., and Roizen M.F. Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol 37 (1997) 25-30
34. Foss J., Du W., Wallin B., Melikian A., and Marbury T. Pharmacokinetics (PK) of IV morphine after single and repeat doses of alvimopan, a novel peripherally acting mu-opioid antagonist in humans. J Pain 6 3, Suppl 1 (2005) S41
35. Foss J., Marbury T.C., Melikian A., Schmith V., Du W., and Wallin B. Pharmacokinetics and safety of alvimopan, a novel, oral, peripherally acting mu-opioid receptor (PAM-OR) antagonist, in patients with renal impairment. Pharmacotherapy 25 (2005) 1504
36. Foss J., Marbury T.C., Melikian A., Schmith V., Du W., and Wallin B. Pharmacokinetics of alvimopan, a novel, oral, peripherally acting mu-opioid receptor (PAM-OR) antagonist, and its primary metabolite in the elderly. Pharmacotherapy 25 (2005) 1505
37. Foss J., Schmith V., Wallin B., Du W., and Melikian A. Alvimopan (Entereg), a novel opioid antagonist, achieves active systemic concentrations. Clin Pharmacol Ther 77 (2005) P74
38. Fukuda H., Suenaga K., Tsuchida D., Mantyh C.R., Pappas T.N., Hicks G.A., et al. The selective mu opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats. Brain Res 1102 (2006) 63-70
39. Gan T.J., Israel R., and Penenberg D.N. Methylnaltrexone in post-operative bowel dysfunction: results of a double-blind, randomized, placebo-controlled trial in segmental colectomy patients. Presentation No. S-281, International Anesthesia Research Society 80th Clinical & Scientific Congress, San Francisco, CA, March 24-28. (2006) Abstract Viewer/Itinerary Planner. Online
40. Garnett W., Kelleher D.L., Hickmott F., Barr W., Zfass A.M., Sanderlin G., et al. Alvimopan (ALV) shortens whole bowel transit time in adults with chronic constipation (CC). Gastroenterology 126 4, Suppl 2 (2004) (Abst W1472)
41. Gervaz P., Bucher P., Scheiwiller A., Mugnier-Konrad B., and Morel P. The duration of postoperative ileus after elective colectomy is correlated to surgical specialization. Int J Colorectal Dis 21 (2006) 542-546
42. Gmerek D.E., Cowan A., and Woods J.H. Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther 236 (1986) 8-13
43. Gonenne J., Camilleri M., Ferber I., Burton D., Baxter K., Keyashian K., et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 3 (2005) 784-791
44. Greenwood-van Meerveld B., Gardner C.J., Little P.J., Hicks G.A., and DeHaven-Hudkins D.L. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 16 Suppl 2 (2004) 46-53
45. Grundy D.J., Booth C.E., Winchester W., and Hicks G.A. Peripheral opiate action on afferent fibers supplying the rat intestine. Neurogastroenterol Motil 16 Suppl 2 (2004) 29-37
46. Hargreaves K.M., and Joris J.L. The peripheral analgesic effects of opioids. APS J 2 (1993) 51-59
47. Hawkes N.D., Rhodes J., Evans B.K., Rhodes P., Hawthorne A.B., and Thomas G.A.O. Naloxone treatment for irritable bowel syndrome - a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 16 (2002) 1649-1654
48. Hedner T., and Cassuto J. Opioids and opioid receptors in peripheral tissues. Scand J Gastroenterol Suppl 130 (1987) 27-46
49. Heel R.C., Brogden R.N., Speight T.M., and Avery G.S. Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 15 (1978) 33-52
50. Ho A., Lievore A., Patierno S., Kohlmeier S.E., Tonini M., and Sternini C. Neurochemically distinct classes of myenteric neurons express the μ-opioid receptor in the guinea pig ileum. J Comp Neurol 458 (2003) 404-411
51. Holte K., and Kehlet H. Postoperative ileus: a preventable event. Br J Surg 87 (2000) 1480-1493
52. Irving G., Hermanns K., Cousins M., Pierce A., Snidow J., Mortensen E., et al. Gastrointestinal adverse events (GIAEs) associated with long-term opioid analgesic therapy in a large, persistent non-cancer pain population [abstract]. American Pain Society 25th Annual Meeting, San Antonio, TX (2006)
53. Kalso E., Edwards J.E., Moore R.A., and McQuay H.J. Opioids in chronic non-cancer pain; systematic review of efficacy and safety. Pain 112 (2004) 372-380
54. Kariv Y., Viscusi E., Wolff B., Delaney C., Senagore A., Du W., et al. Efficacy of alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist, and timing of preoperative dosing: pharmacodynamic and pharmacokinetic consideration in patients undergoing open laparotomy. Pharmacotheraphy 25 (2005) 1505
55. Kehlet H., and Holte K. Review of postoperative ileus. Am J Surg 182 (2001) 3S-10S
56. Koblish M., Little P.J., Sharpless L.C., and DeHaven-Hudkins D.L. Behavioral profile of ADL 8-2698, a novel GI-restricted μ opioid receptor antagonist. Soc Neurosci Abstr 27 (2001) 907.3
57. Kosterlitz H.W., Lord J.A.H., and Watt A.J. Morphine receptor in the myenteric plexus of the guinea-pig ileum. In: Kosterlitz H.W., Collier H.O.J., and Villareal J.E. (Eds). Agonist and Antagonist Actions of Narcotic Analgesic Drugs. (1972), Macmillan Press, London
58. Kotake A.N., Kuwahara S.K., Burton E., McCoy C.E., and Goldberg L.I. Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica 19 (1989) 1247-1254
59. Kreek M.-J., Schaefer R.A., Hahn E.F., and Fishman J. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet 1 8319 (1983) 261-262
60. Kreek M.J., Paris P., Bartol M.A., and Mueller D. Effects of short term oral administration of the specific opioid antagonist naloxone on fecal evacuation in geriatric patients. Gastroenterology 86 (1984) 1144
61. Kromer W. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol Rev 40 (1988) 121-162
62. Kurz A., and Sessler D. Opioid-induced bowel dysfunction. Pathophysiology and potential new therapies. Drugs 63 (2003) 649-671
63. Latasch L., Zimmermann M., Eberhardt B., and Jurna I. Oral naloxone antagonizes morphine-induced constipation. Anaesthesist 46 (1997) 191-194
64. Liberto J.G., Herschler J.A., Jaffe J.H., Norbeck J.H., and Carpenter R.L. Effects of ADL 8-2698, a peripherally restricted mu opioid antagonist, on gut motility in methadone and LAAM-dependent patients with opioid-induced constipation: a dose-ranging study. Drug Alcohol Depend 63 (2001) S91
65. Little P.J., Long S.L., Gottshall S.L., Koblish M., Guo D., and DeHaven-Hudkins D.L. Pharmacological profile of ADL 8-2698, a peripherally restricted opioid receptor antagonist. International Narcotics Research Conference, Seattle, WA, July 15-20 (2000)
66. Little P.J., Koblish M., DeHaven-Hudkins D.L., Pietras M.R., and Cowan A. ADL 8-2698, a GI restricted opioid antagonist, blocks the antisecretory and colorectal transit effects of morphine and loperamide. Soc Neurosci Abstr 27 (2001) 907.2
67. Liu M., and Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 23 (2002) 48-53
68. Liu S.S., Hodgson P.S., Carpenter R.L., and Fricke J.R. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 69 (2001) 66-71
69. Locke K.W., and Holtzman S.G. Characterization of the discriminative stimulus effects of centrally administered morphine in the rat. Psychopharmacology 87 (1985) 1-6
70. Long S., Little P.J., Gaul F., Guo D., Koblish M., and DeHaven-Hudkins D.L. Effects of novel μ-opioid antagonists on gastrointestinal (GI) transit in mice. Soc Neurosci Abstr 25 (1999) 1706
71. Ludwig K.A., Enker W.E., Delaney C.P., Wolff B.G., Du W., and Techner L. Accelerated gastrointestinal recovery and reduced length of stay following modified preoperative dose timing with alvimopan: results of a large, randomized, placebo-controlled study in partial bowel resection. American College of Surgeons 92nd Annual Clinical Congress; October 8-12, 2006; Chicago, IL (2006)
72. McMillan S.C. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 11 Suppl. 1 (2004) 3-9
73. Meissner W., Schmidt U., Hartmann M., Kath R., and Reinhart K. Oral naloxone reverses opioid-induced constipation. Pain 84 (2000) 105-109
74. Mickley G.A., Stevens K.E., and Galbraith J.A. Quaternary naltrexone reverses morphine-induced behaviors. Physiol Behav 35 (1985) 249-253
75. 3H]naltrexonium methiodide in the rat. J Pharm Pharmacol 39 (1987) 225-227
76. Moerman I., Franck P., and Camu F. Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences. Acta Anaesthesiol Belg 46 (1995) 127-132
77. Morlion B., Aggarwal N., Frank L., Rentz A., Kleoudis C., and Bell T. Efficacy of alvimopan, a peripheral opioid receptor antagonist, for the management of gastrointestinal adverse events (GIAEs) associated with opioid use: assessment using the PAC-SYM questionnaire. [abstract]. American Pain Society 25th Annual Meeting, San Antonio, TX (2006)
78. Murphy D.B., Sutton J.A., Prescott L.F., and Murphy M.B. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 87 (1997) 765-770
79. Niemegeers C.J.E., Colpaert F.C., and Awouters F.H.L. Pharmacology and antidiarrheal effect of loperamide. Drug Dev Res 1 (1981) 1-20
80. Nishimura E., Buchan A.M.J., and McIntosh C.H.S. Autoradiographic localization of μ- and δ-type opioid receptors in the gastrointestinal tract of the rat and guinea pig. Gastroenterology 91 (1986) 1084-1094
81. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182 5A Suppl (2001) 11S-18S
82. Patierno S., Raybould H.E., and Sternini C. Abdominal surgery induces μ-opioid receptor endocytosis in enteric neurons of the guinea-pig ileum. Neuroscience 123 (2004) 101-109
83. Paulson D.M., Kennedy D.T., Panebianco D.I., Talluri K., and Carpenter R.L. A forced titration, dose ranging study of alvimopan for the reversal of opioid-induced bowel dysfunction. Presented at the 10th World Congress on Pain; August 17-22, 2002; San Diego, CA. 2002 Abstracts Viewer/Itinerary Planner (2002), IASP Press, Seattle, WA 197 (Online)
84. Paulson D.M., Kennedy D.T., Donovick R.A., Carpenter R.L., Cherubini M., Techner L., et al. Alvimopan: an oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial. J Pain 6 (2005) 184-192
85. Pol O., Alameda F., and Puig M.M. Inflammation enhances μ-opioid receptor transcription and expression in mice intestine. Mol Pharmacol 60 (2001) 894-899
86. Quito F.L., Seybold V.S., and Brown D.R. Opiate binding sites in mucosa of pig small intestine. Life Sci 49 (1991) PL-219-PL-222
87. Rauck R.L., Southern J.P., and Carpenter R.L. Use of alvimopan, a peripherally restricted μ-opioid antagonist, to speed gastrointestinal transit in patients with opioid induced bowel dysfunction. Presented at the 10th World Congress on Pain; August 17-22, 2002; San Diego, CA. Abstracts Viewer / Itinerary Planner (2002), IASP Press, Seattle, WA 550-551 (Online)
88. Reynolds I.J., Gould R.J., and Snyder S.H. Loperamide: blockade of calcium channels as a mechanism for antidiarrheal effects. J Pharmacol Exp Ther 231 (1984) 628-632
89. Robinson B.A., Johansson L., and Shaw J. Oral naloxone in opioid-associated constipation. Lancet 338 (1991) 581-582
90. Russell J., Bass P., Goldberg L.I., Schuster C.R., and Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 78 (1982) 255-261
91. Sanger G.J., and Tuladhar B.R. The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modeling. Neurogastroenterol Motil 16 Suppl. 2 (2004) 38-45
92. Schinkel A.H., Wagenaar E., Mol C.A.A.M., and van Deemter L. P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97 (1996) 2517-2524
93. Schmidt W.K. Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 182 (2001) 27S-38S
94. Schmith V., Garnett W., Barr W.H., Kelleher D., Young M., Sanderlin G., et al. Alvimopan pharmacokinetics (PK) & pharmacodynamics (PD) in patients with chronic constipation. Clin Pharmacol Ther 77 (2005) P49
95. Sharma N., Akca O., Schmidt W.K., and Kurz A. Evaluation of a new μ-opioid antagonist for the management of postoperative ileus: additional Phase II study results. Anesthesiology 96 (2002) A452
96. Slatkin N., Thomas J., Lipman A., Wilson G., Moehl M., Wellman C., et al. A phase III double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness (AMI). 11th World Congress on Pain; August 22, 2005; Sydney, Australia. Abstracts Viewer/Itinerary Planner. (2005), IASP Press, Seattle, WA (Online)
97. Stein C., Millan M.J., Shippenberg T.S., Peter K., and Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 248 (1989) 1269-1275
98. Stein C., Schafer M., and Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med 9 (2003) 1003-1008
99. Sternini C. Receptors and transmission in the brain-gut axis: potential for novel therapies III. μ-Opioid receptors in the enteric nervous system. Am J Physiol Gastrointest Liver Physiol 281 (2001) G8-G15
100. Sternini C., Patierno S., Selmer I.-S., and Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 16 Suppl. 2 (2004) 3-16
101. Sykes N.P. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 10 (1996) 135-144
102. Taguchi A., Sharma N., Saleem R.M., Sessler D.I., Carpenter R.L., Seyedsadr M., et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 345 (2001) 935-940
103. Tark M., Sabatowski R., Frank L., Rentz A., Kleoudis C., and Bell T. Effect of alvimopan, a peripheral opioid receptor antagonist, on health-related quality of life (HRQOL) in patients who develop gastrointestinal adverse events (GIAEs) while taking opioids for persistent non-cancer pain [abstract]. American Pain Society 25th Annual Meeting, San Antonio, TX (2006)
104. Thomas J., Portenoy R., Moehl M., Von Gunten C., Thielemann P., Stambler N., et al. A phase II randomized dose-finding trial of methylnaltrexone for the relief of opioid-induced constipation in hospice patients. American Society of Clinical Oncology Annual Meeting, Abstract No. 2933. Chicago, IL, May 30-June 3. Abstracts Viewer/Itinerary Planner. Online (2003)
105. Thomas J., Lipman A., Slatkin N., Wilson G., Moehl M., Wellman C., et al. A phase III double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness (AMI). 2005 American Society of Clinical Oncology Annual Meeting, Abstract No. 8003. Orlando, FL, May 13-17. Abstracts Viewer/Itinerary Planner. Online (2005)
106. Valentino R.J., Katz J.L., Medzihradsky F., and Woods J.H. Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci 32 (1983) 2887-2896
107. Viscusi E., Goldstein S., Witkowski T., Andonakakis A., Jan R., Gabriel K., et al. Alvimopan, a novel peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery. Surg Endosc 20 (2006) 64-70
108. Viscusi E., Leslie J., Fort J., Du W., and Techner L. Alvimopan, a novel peripherally acting mu-opioid receptor antagonist, does not affect opioid-based, centrally-mediated analgesia follwing surgery. [abstract]. American Pain Society 25th Annual Meeting, San Antonio, TX (2006)
109. Webster L., Jansen J., Peppin J., Lasko B., Snidow J., Pierce A., et al. A randomized, double-blind, placebo-controlled, multicenter phase IIb study to evaluate the efficacy and safety of multiple alvimopan dosage regimens for the treatment of gastrointestinal adverse events (GIAEs) associated with opioid use in subjects. [abstract]. American Pain Society 25th Annual Meeting, San Antonio, TX (2006)
110. Willette R.N., Krieger A.J., and Sapru H.N. Evidence for anticholinergic effects of naltrexone methylbromide. Res Commun Subst Abuse 4 (1983) 325-337
111. Wolff B.G., Michelassi F., Gerkin T.M., Techner L., Gabriel K., Du W., et al. Alvimopan, a novel, peripherally acting μ-opioid antagonist. Results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 240 (2004) 728-735
112. Wood J.D., and Galligan J.J. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 16 Suppl. 2 (2004) 17-28
113. Woods M.S. Postoperative ileus: dogma versus data from bench to bedside. Perspect Colon Rectal Surg 12 (2000) 57-76
114. Yuan C.-S. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects. J Support Oncol 2 (2004) 111-122
115. Yuan C.-S., and Foss J.F. Methylnaltrexone: investigation of clinical applications. Drug Dev Res 50 (2000) 133-141
116. Yuan C.-S., and Foss J.F. Oral methylnaltrexone for opioid-induced constipation. J Am Med Assoc 284 (2000) 1383-1384
117. Yuan C.-S., Foss J.F., and Moss J. Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur J Pharmacol 276 (1995) 107-111
118. Yuan C.-S., Foss J.F., O'Connor M., Toledano A., Roizen M.F., and Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 59 (1996) 469-475
119. Yuan C.S., Foss J.F., Osinski J., Toledano A., Roizen M.F., and Moss J. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 61 (1997) 467-475
120. Yuan C.S., Foss J.F., O'Connor M., Osinski J., Roizen M.F., and Moss J. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 52 (1998) 161-165
121. Yuan C.S., Foss J.F., O'Connor M., Osinski J., Roizen M.F., and Moss J. Effect of intravenous methylnaltrexone in opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain 83 (1999) 631-635
122. Yuan C.-S., Foss J.F., O'Connor M., Karrison T., Osinski J., Roizen M.F., et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 67 (2000) 398-404
123. Yuan C.S., Foss J.F., O'Connor M., Osinski J., Karrison T., Moss J., et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. J Am Med Assoc 283 (2000) 367-372
124. Yuan C.S., Wei G., Foss J.F., O'Connor M., Karrison T., and Osinski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 300 (2002) 118-123
125. Yuan C.-S., Doshan H., Charney M.R., O'Connor M., Karrison T., Maleckar S.A., et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 45 (2005) 538-546
126. Zimmerman D.M., Gidda J.S., Cantrell B.E., Schoepp D.D., Johnson B.G., and Leander J.D. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem 37 (1994) 2262-2265
127. Zimmerman D.M., Gidda J.S., Cantrell B.E., Werner J.A., Parli C.J., Franklin R.B., et al. LY246736 dihydrate. Drugs Future 19 (1994) 1078-1083
128. Zollner C., Shaqura M.A., Bopaiah C.P., Mousa S., Stein C., and Schafer M. Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol Pharmacol 64 (2003) 202-210